Detection of platinum-DNA adducts by 32P-postlabelling.

@article{Blommaert1995DetectionOP,
  title={Detection of platinum-DNA adducts by 32P-postlabelling.},
  author={F. A. Blommaert and C. Saris},
  journal={Nucleic acids research},
  year={1995},
  volume={23 8},
  pages={
          1300-6
        }
}
We developed a sensitive 32P-postlabeling method for the detection of bifunctional intrastrand crosslinks d(Pt-GpG) and d(Pt-ApG) in DNA in vitro and in vivo. After enzymatic digestion of DNA the positively charged platinum adducts were purified from unplatinated products, using strong cation exchange chromatography. Subsequently the samples were deplatinated with cyanide, because platinated dinucleotides are very poor substrates for polynucleotide kinase. The excess of cyanide was removed… Expand
Improved 32P-postlabelling assay for the quantification of the major platinum-DNA adducts.
TLDR
The 32P-postlabelling assay, described by Blommaert and Saris, to detect the major adducts Pt-GG and Pt-AG has substantially been improved and compared with ELISA and AAS and shows a significant correlation with the adduct levels as determined with atomic absorption spectroscopy or with specific antibodies. Expand
32P-postlabeling assay for the quantification of the major platinum-DNA adducts.
TLDR
The assay is now routinely used for high-precision analyses of patient and cell line samples containing very low adduct levels and the between- and within-run precision for the Pt-GG and Pt-AG adducts measured at the lower limit of quantification of 87 and 53 amol/microg DNA, respectively. Expand
The 32P-postlabeling assay for DNA adducts
TLDR
The assay requires only microgram quantities of DNA and is capable of detecting adducts at frequencies as low as 1 in 1010 nt, making it applicable to the detection of events resulting from environmental exposures, or experiments using physiological concentrations of agents. Expand
Detection of DNA modifications by the 32P-postlabelling assay.
TLDR
There is a case to be made for the use of more standardised protocols, particularly where human exposure to carcinogens is being measured and where such results may be required for risk assessment, and the efficiency of adduct labelling is, in many cases, not quantitative. Expand
On the origins and development of the (32)P-postlabelling assay for carcinogen-DNA adducts.
TLDR
The (32)P-postlabelling method for the analysis of carcinogen-DNA adducts originated 30years ago from Baylor College of Medicine in Houston and was the work of a team comprised of Kurt and Erica Randerath, Ramesh Gupta and Vijay Reddy, and has become a highly sensitive and versatile method that has been applied in a wide range of human, animal and in vitro studies. Expand
In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells.
TLDR
The 32P-postlabelling technique has been shown to be appropriate for adduct analysis, not only for the classical Pt compounds cisplatin and carboplatin but also for novel platinum compounds like lobaplatinand oxaliplatin. Expand
Transplatin-conjugated triplex-forming oligonucleotides form adducts with both strands of DNA.
TLDR
It is reported that attachment of N-7-platinated guanine nucleosides to the 3'- and/or 5'-ends of oligopyrimidine TFOs enables these TFO's to form highly stable adducts with target DNA deoxyguanosines or deoxyadenosines that are adjacent to the TFO binding site. Expand
Development of an ultraperformance liquid chromatography/mass spectrometry method to quantify cisplatin 1,2 intrastrand guanine-guanine adducts.
TLDR
An ultraperformance liquid chromatography tandem mass spectrometry assay for quantification of 1,2 guanine-guanine intrastrand cisplatin adducts, using (15)N(10) CP-d(GpG) as an internal standard, was developed and suggested that this method is suitable for in vitro and in vivo assessment. Expand
Adduct-specific monoclonal antibodies for the measurement of cisplatin-induced DNA lesions in individual cell nuclei
TLDR
A new method to establish and characterize monoclonal antibodies (Mab) for structurally defined DNA adducts is described, allowing the quantification of drug-induced lesions in individual cell nuclei at clinically relevant doses. Expand
Separation and identification of platinum adducts with DNA nucleotides by capillary zone electrophoresis and capillary zone electrophoresis coupled to mass spectrometry
TLDR
Investigation of the formation of adducts following the reaction of cis‐diamminedichloroplatinum (II) (cisplatin) with various DNA nucleotides and its potential applications comprise studies of novel platinum complexes, investigations of platinum‐adduct formation with DNA, and determination of Platinum‐DNA adductS in cells. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 26 REFERENCES
Carcinogenesis
  • W. Gardner
  • The Yale Journal of Biology and Medicine
  • 1961
in their respective fields. The chapters on adrenocorticotrophin, oxytocin, and vasopressin are not very inspiring. This book will be a useful reference book for research endocrinologists or thoseExpand
Biochemistry
The Department of Biochemistry is internationally recognized for its research and education and offers a world-class interdisciplinary research environment in a beautiful mountain setting. As part ofExpand
Interactions 74,45-54
  • Pmc
  • 1994
Cancer Res
  • Cancer Res
  • 1993
Cancer Res. S3
  • Cancer Res. S3
  • 1993
Environ. Health Perspect
  • Environ. Health Perspect
  • 1993
IARC Scientific Publications
  • IARC Scientific Publications
  • 1993
Oncology Research Nucleic Acids Res
  • Oncology Research Nucleic Acids Res
  • 1993
Biochemistry 31, 11812-11818
  • 19 Oshita, F., & Eastman, A. (1993). Oncology Research 5, 111-118. 20 Grimaldi, K. A., McAdam, S. R., Souhami, R. L. & Hartley, J. A. (1994)
  • 1992
Cancer Metast. Rev
  • Cancer Metast. Rev
  • 1992
...
1
2
3
...